New Article Reveals Trend Toward Greater Use of Human Menopausal Gonadotropin in In Vitro Fertilization

PARSIPPANY, N.J., March 8 /PRNewswire/ — The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, “Gonadotropins in the Treatment of Infertility” by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals.(1)  The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.

View the full article at PR Newswire